Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation

https://doi.org/10.20996/1819-6446-2015-11-5-510-516

Full Text:

Abstract

Background. According to the some studies tocilizumab therapy (TCZ) in patients with rheumatoid arthritis (RA) is accompanied by deterioration of blood lipid profile.
Aim. To study changes in serum lipid parameters in patients with RA treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation.
Material and methods. Patients (n=72) with RA were included into the pilot non-randomized 24-week study and divided in two groups: 1) TCZ+MTX group (n=39; women 30; median age 51 [43-55] years; 6 i.v. infusions of TCZ 8 mg/kg + МТX 10-20 mg/week); 2) MTX group (n=33; women 23; mеdian age 56 [48-63] years; MTX 7.5-20 mg/week).
Results. At the baseline, similar proatherogenic blood profile was observed in both groups. The patients of MTX group more frequently took statins (n=19; 57.6%) compared with the group TCZ+MTX (n=7; 18%), (p<0.05). The lipid levels correlated positively with traditional risk factors (p<0.05). RA activity and duration correlated negatively with high density lipoprotein cholesterol (HDL-C), (p<0.05). Good/satisfactory anti-inflammatory effect was achieved in both groups after 24 weeks of treatment. Patients of TCZ+MTX group showed an increase in total cholesterol and HDL-C levels by 11% and 110%, respectively and decrease in plasma atherogenic index (PAI) by 47%, (p<0.05). HDL-C level increased by 22% and PAI decreased by 16% in patients of MTX group (p<0.05). Among patients of MTX group without statin therapy HDL-C as well as non-HDL-C levels were increased by 24% and 27%, respectively (p<0.05); PAI did not change significantly in this subgroup. Among patients of MTX group treated with statins isolated increase in HDL-C level by 22% and decrease in PAI by 37.3% (p<0.05) were observed. A number of patients with achieved target levels of all studied lipid parameters did not change significantly in both groups.
Conclusions. TCZ+MTX combined therapy as well as MTX monotherapy are associated with similar improvement in lipid parameters. Adjusted statin doses may be needed to achieve target serum lipid profile in RA patients.

About the Authors

E. V. Udachkina
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


D. S. Novikova
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


E. Yu. Panasyuk
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


A. S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


A. V. Volkov
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


I. G. Kirillova
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


E. I. Markelova
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


E. N. Aleksandrova
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


A. A. Novikov
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 Russia
Russian Federation


References

1. Nasonov EL, Nasonov VA, eds. Rheumatoid arthritis. Moscow: GEOTAR Media; 2008. In Russian (Насонов Е.Л., Насонова В.А., ред. Ревматоидный артрит. Москва: ГЭОТАР-Медиа; 2008).

2. Peters M.J., Symmons D.P., McCarey D.W. et al. EULAR evidence-based recomendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2010;69(2):325-31.

3. del Rincon I., Williams K., Stern M.P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.

4. Udachkina EV, Novikova DS, Popkov TV, Nasonov EL. The role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis. Sovremennaya Revmatologiya 2013; 3: 25-32. In Russian (Удачкина Е. В., Новикова Д. С., Попкова Т. В., Насонов Е. Л. Роль интерлейкина-6 в развитии атеросклероза при ревматоидном артрите. Современная Ревматология 2013; 3: 25-32).

5. Nasonov EL. Application of tocilizumab (Actemra) in rheumatoid arthritis. Nauchno-prakticheskaya Revmatologiya 2009; 3:18-35. In Russian (Насонов Е.Л. Применение тоцилизумаба (Актемры) при ревматоидном артрите. Научно-практическая Ревматология 2009; 3:18-35).

6. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379(9822):1205-13.

7. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379(9822):1214-24.

8. Popkova TV, Novikova DS, Panasyuk EY, Avdeeva AS. Influence of tocilizumab on transport system of blood cholesterol and early signs of atherosclerosis in patients with rheumatoid arthritis. Terapevticheskiy Arkhiv 2012; 5: 10-8. In Russian (Попкова Т.В., Новикова Д.С., Панасюк Е.Ю., Авдеева А.С. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический Архив 2012; 5: 10-8).

9. McInnes I.B., Thompson L., Giles J.T., Bathon J.M. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015;74(4):694-702.

10. Souto A., Salgado E., Maneiro J.R. et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015;67(1):117-27.

11. The national guidelines for the diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis (V revision). Rossiyskiy Kardiologicheskiy Zhurnal 2012; 4 (Supplement 1): 1-32. In Russian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (V пересмотр). Российский Кардиологический Журнал 2012; 4 (Приложение 1): 1-32).

12. De Vecchis R., Baldi C., Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anadolu Kardiyol Derg 2015 Feb 16. doi: 10.5152/akd.2015.6136.

13. Ronda N., Greco D., Adorni M.P. et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism Arthritis Rheumatol 2015;67(5):1155-64.

14. Davis L.A., Cannon G.W., Pointer L.F., Haverhals L.M. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. J Rheumatol 2013;40(6):809-17.

15. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7 Suppl 1:332-9.

16. Micha R., Imamura F., Wyler von Ballmoos M., Solomon D.H. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011 Nov 1;108(9):1362-70.

17. Chen D.Y., Chih H.M., Lan J.L., Chang H.Y. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011;9:4.

18. Reiss A.B., Carsons S.E., Anwar K., Rao S. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58(12):3675-83.

19. Marks J.L., Edwards C.J. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012;4(3):149-57.

20. Coomes E., Chan E.S., Reiss A.B. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. 2011;2011:503028.

21. Westlake S.L., Colebatch A.N., Baird J., Kiely P. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Feb;49(2):295-307.

22. González-Gay M.A., González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014;73:1281-3.

23. Genovese M.C., Smolen J.S., Emery P. et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: analysis of five phase 3 clinical trials. Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting; October 24-29, 2008; San Francisco, California. Abstract 1672.


For citation:


Udachkina E.V., Novikova D.S., Popkova T.V., Panasyuk E.Y., Avdeeva A.S., Volkov A.V., Kirillova I.G., Markelova E.I., Aleksandrova E.N., Novikov A.A., Nasonov E.L. Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation. Rational Pharmacotherapy in Cardiology. 2015;11(5):510-516. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-5-510-516

Views: 419


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)